Agenus to Present at Jefferies 2014 Global Healthcare Conference
May 30 2014 - 7:00AM
Business Wire
Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company
developing a portfolio of checkpoint modulators (CPMs), heat shock
protein vaccines and adjuvants, today announced that Robert Stein,
MD, PhD, the company’s Chief Scientific Officer, is scheduled to
present a company overview at the Jefferies 2014 Global Healthcare
Conference in New York City on Thursday, June 5th at 1:00 pm
ET.
Web Cast Information
The live and archived webcast of the company presentation will
be accessible from the company’s website at
www.agenusbio.com/webcast. Please log in approximately 5-10 minutes
before each event to ensure a timely connection. The archived
replay will be available on the Agenus website for one month
following the conference.
About Agenus
Agenus is an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein vaccines and
adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40,
CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery
engine Retrocyte Display® is used to generate fully human
therapeutic antibody drug candidates. The Retrocyte Display
platform uses a high-throughput approach incorporating IgG format
human antibody libraries expressed in mammalian B-lineage cells.
Agenus’ heat shock protein vaccines for cancer and infectious
disease are in Phase 2 studies. The company’s QS-21 Stimulon®
adjuvant platform is extensively partnered with GlaxoSmithKline and
Janssen and includes several candidates in Phase 3 trials. Among
Agenus and its partners, 22 programs are in clinical development.
For more information, please visit www.agenusbio.com, or connect
with the company on Facebook, LinkedIn, Twitter and Google+. For
more information, please visit www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding corporate presentations, research,
development and clinical trial activities, and the potential
application of the Company’s technologies and product candidates in
the prevention and treatment of diseases. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission for the period ended March 31,
2014. Agenus cautions investors not to place considerable reliance
on the forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus
undertakes no obligation to update or revise the statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Agenus’ business is subject
to substantial risks and uncertainties, including those identified
above. When evaluating Agenus’ business and securities, investors
should give careful consideration to these risks and
uncertainties.
Media and Investor Contact:Jonae R. Barnes,
617-818-2985Vice PresidentInvestor Relations andCorporate
Communicationsjonae.barnes@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024